Images

[From OUT magazine, August 31, 2018] “A mere 4% of gay and bisexual men reported using Truvada as PrEP in a new study, recently published in PLOS ONE. Led by Psychology Professor Phillip Hammack of the University of California Santa Cruz, the study examined HIV testing and use, familiarity, and attitudes toward pre-exposure prophylaxis (PrEP) among HIV-negative […]

[From NBC, August 31, 2018] “More than one in nine people worldwide who might benefit from a daily pill to minimize their risk of getting HIV are now taking this medicine, a research review suggests.” For more, click here.

[From aidsmap, August 31, 2018] “The US Food and Drug Administration (FDA) has approved two new products containing the next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) doravirine. These products are also under review by the European Medicines Agency.” For more, click here.

[From National Institute of Health, August 31, 2018] “An intervention designed to facilitate treatment for HIV and substance use was associated with a 50 percent reduction in mortality for people living with HIV who inject illicit drugs, a study has found. In addition, the people who received the intervention were nearly twice as likely to report

[From CBC, August 30, 2018] “Alberta will be providing universal coverage for PrEP — an HIV-prevention drug that is up to 99 per cent effective at stopping the transmission of the disease — beginning Oct. 1. “It’s about public health. It’s about promoting health and preventing illness,” said Premier Rachel Notley at a surprise announcement during